Drug profile

The FDA adverse-event record for Triamcinolone Acetonide 0.147 Mg/G

19 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Triamcinolone Acetonide 0.147 Mg/G. See the species affected, top reactions, and outcomes below.

19
adverse-event reports
10.5%
death-coded share
Dog
most-reported species
5
Other abnormal test result NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
19
Total Reports
2
Deaths Reported
10.5%
Death Rate

Active Ingredients

Triamcinolone Acetonide 0.147 Mg/G

Administration Routes

UnknownTopicalIntramuscular

Species Affected

Dog 17
Cat 2

Most Affected Breeds

Chow Chow 2
Terrier - Yorkshire 2
Terrier - Bull - American Pit 2
Domestic Shorthair 2
Bichon Frise 2
Shar Pei 1
Poodle - Miniature 1
Mixed (Dog) 1
Bulldog 1
Retriever - Labrador 1

Most Reported Reactions

Other abnormal test result NOS 5
Seizure NOS 4
Vomiting 4
Facial swelling (see also 'Skin') 3
Bloody diarrhoea 3
Diarrhoea 2
Elevated serum alkaline phosphatase (SAP) 2
Lethargy (see also Central nervous system depression in 'Neurological') 2
Inappetence 2
Abnormal radiograph finding 2
Elevated gamma-glutamyl transferase (GGT) 2
Anxiety 2

Outcome Breakdown

Ongoing
12 (63.2%)
Recovered/Normal
4 (21.1%)
Died
2 (10.5%)
Outcome Unknown
1 (5.3%)

Triamcinolone Acetonide 0.147 Mg/G Adverse Event Insights

19 reports name Triamcinolone Acetonide 0.147 Mg/G; 2 recorded a death outcome (10.5% of reported events, not a population-level mortality rate). Active ingredient: Triamcinolone Acetonide 0.147 Mg/G. Administration routes: Unknown, Topical, Intramuscular.

By species: Dog (17 reports), Cat (2 reports). By breed: Chow Chow (2), Terrier - Yorkshire (2), Terrier - Bull - American Pit (2).

Leading clinical signs: Other abnormal test result NOS (5), Seizure NOS (4), Vomiting (4), Facial swelling (see also 'Skin') (3). Outcome, 19 coded reports: Ongoing leads at 63.2%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.